# Evogene (EVGN) — Earnings

EVGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/evgn/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.14 |
| EPS estimate | −$0.27 |
| EPS surprise | +48.15% |
| Revenue surprise | +6.77% |
| Revenue | $347,000.00 |
| Revenue estimate | $325,000.00 |
| Reported | Aug 18, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1574565/000117891326004174/zk2635981.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/d113fc58-8a64-ab30-e5fc-7956ec9416b2.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 18, 2026 | −$0.27 | −$0.14 | 48.15% | $325,000.00 | $347,000.00 |
| Q1 2026 | May 20, 2026 | −$0.27 | −$0.60 | -122.22% | $350,000.00 | $334,000.00 |
| Q4 2025 | Mar 5, 2026 | −$0.26 | −$0.61 | -134.23% | $275,000.00 | $314,000.00 |
| Q3 2025 | Nov 20, 2025 | −$0.41 | $0.44 | 208.39% | $650,000.00 | $312,000.00 |
| Q2 2025 | Aug 19, 2025 | −$0.63 | −$0.50 | 20.63% | $930,000.00 | $884,000.00 |
| Q1 2025 | May 21, 2025 | −$0.51 | −$0.38 | 24.75% | $4.4M | $2.4M |
| Q4 2024 | Mar 6, 2025 | −$0.73 | $0.06 | 108.28% | $3.6M | $1.6M |
| Q3 2024 | Nov 21, 2024 | −$1.01 | −$1.31 | -29.70% | $2.9M | $1.8M |
| Q2 2024 | Aug 22, 2024 | −$1.25 | −$1.06 | 15.20% | $775,000.00 | $914,000.00 |
| Q1 2024 | May 23, 2024 | −$0.95 | −$0.80 | 15.79% | $3.4M | $4.2M |
| Q4 2023 | Mar 7, 2024 | −$1.40 | −$1.30 | 7.14% | $475,000.00 | $578,000.00 |
| Q3 2023 | Nov 15, 2023 | −$1.57 | −$0.80 | 48.94% | $1.2M | $3.8M |
| Q2 2023 | Aug 17, 2023 | −$1.75 | −$1.70 | 2.86% | $885,000.00 | $654,000.00 |
| Q1 2023 | May 18, 2023 | −$1.60 | −$1.50 | 6.25% | $685,000.00 | $641,000.00 |
| Q4 2022 | Mar 9, 2023 | −$2.00 | −$0.70 | 65.00% | $450,000.00 | $660,000.00 |
| Q3 2022 | Nov 17, 2022 | −$1.97 | −$1.60 | 18.65% | $234,667.00 | $466,000.00 |
| Q2 2022 | Aug 31, 2022 | −$1.90 | −$2.10 | -10.53% | $230,667.00 | $312,000.00 |
| Q1 2022 | May 26, 2022 | −$1.80 | −$2.00 | -11.11% | $309,000.00 | $237,000.00 |
| Q4 2021 | Mar 10, 2022 | −$2.00 | −$1.80 | 10.00% | $184,333.00 | $311,000.00 |
| Q3 2021 | Nov 17, 2021 | −$1.77 | −$1.90 | -7.55% | $112,000.00 | $151,000.00 |

## Frequently Asked Questions

### When did Evogene (EVGN) last report earnings?

Evogene last reported on Aug 18, 2026, covering fiscal Q2 2026.

### Did EVGN beat earnings estimates?

Yes. Evogene reported EPS of −$0.14 for Q2 2026 against a −$0.27 estimate — a 48.15% beat.

### How much revenue did EVGN report last quarter?

Evogene reported $347,000.00 in revenue for Q2 2026, against a consensus estimate of $325,000.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).